ATE109023T1 - Mikrokugeln aus denen wasserlösliche materialien mit vorbestimmter geschwindigkeit freigesetzt werden, und verfahren zur herstellung derselben. - Google Patents

Mikrokugeln aus denen wasserlösliche materialien mit vorbestimmter geschwindigkeit freigesetzt werden, und verfahren zur herstellung derselben.

Info

Publication number
ATE109023T1
ATE109023T1 AT91903868T AT91903868T ATE109023T1 AT E109023 T1 ATE109023 T1 AT E109023T1 AT 91903868 T AT91903868 T AT 91903868T AT 91903868 T AT91903868 T AT 91903868T AT E109023 T1 ATE109023 T1 AT E109023T1
Authority
AT
Austria
Prior art keywords
water
polymer
miscible
substance
microballs
Prior art date
Application number
AT91903868T
Other languages
English (en)
Inventor
Henri Wantier
Fabienne Mathieu
Marc Baudrihaye
Dominique Delacroix
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE109023T1 publication Critical patent/ATE109023T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/12—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/12—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution
    • B01J13/125—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution by evaporation of the solvent

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT91903868T 1990-02-22 1991-02-18 Mikrokugeln aus denen wasserlösliche materialien mit vorbestimmter geschwindigkeit freigesetzt werden, und verfahren zur herstellung derselben. ATE109023T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR909002189A FR2658432B1 (fr) 1990-02-22 1990-02-22 Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.

Publications (1)

Publication Number Publication Date
ATE109023T1 true ATE109023T1 (de) 1994-08-15

Family

ID=9394021

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91903868T ATE109023T1 (de) 1990-02-22 1991-02-18 Mikrokugeln aus denen wasserlösliche materialien mit vorbestimmter geschwindigkeit freigesetzt werden, und verfahren zur herstellung derselben.

Country Status (7)

Country Link
EP (1) EP0469110B1 (de)
JP (1) JP3512408B2 (de)
AT (1) ATE109023T1 (de)
CA (1) CA2053913C (de)
DE (1) DE69103104T2 (de)
FR (1) FR2658432B1 (de)
WO (1) WO1991012882A1 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US6514533B1 (en) 1992-06-11 2003-02-04 Alkermas Controlled Therapeutics, Inc. Device for the sustained release of aggregation-stabilized, biologically active agent
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
AU680422B2 (en) * 1992-06-11 1997-07-31 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
EP0646000A4 (de) * 1992-11-16 1997-05-02 Univ Mercer Zusammensetzungen, die mikroverkapselte neutralisierende antikörper enthalten.
JPH08503950A (ja) * 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
WO1995011009A1 (en) * 1993-10-22 1995-04-27 Genentech, Inc. Method for preparing microspheres comprising a fluidized bed drying step
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US5843742A (en) * 1994-12-16 1998-12-01 Avigen Incorporated Adeno-associated derived vector systems for gene delivery and integration into target cells
CN1069827C (zh) * 1995-06-09 2001-08-22 浙江大学 一种多肽蛋白质药物微球的制备方法
AU710347B2 (en) * 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
JP2909418B2 (ja) * 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2324568A1 (en) 1998-03-20 1999-09-30 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active polypeptide and production thereof
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
EP1194449B1 (de) 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitoren des memapsin 2 und ihre verwendung
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
SI1650221T1 (sl) 2000-02-23 2012-09-28 Glaxosmithkline Biolog Sa Nove spojine
EP1319069B1 (de) 2000-06-28 2008-05-21 Corixa Corporation Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
AU2002305914A1 (en) 2001-01-12 2002-10-21 Chiron Corporation Nucleic acid mucosal immunization
CA2446788A1 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1409694A4 (de) 2001-07-05 2006-02-08 Chiron Corp Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
EP1581119B1 (de) 2001-12-17 2013-01-30 Corixa Corporation Zusammensetzungen und verfahren zur behandlung und diagnose von entzündlicher darmerkrankung
SI1589934T1 (sl) 2003-01-06 2016-02-29 Corixa Corporation Corporation Service Company Določene aminoalkil glukozaminid fosfat spojine in njih uporaba
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
EP1628680B1 (de) 2003-05-15 2012-10-24 Novartis Vaccines and Diagnostics, Inc. Hiv polynucleotide und polypeptide von botswana mj4
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
ES2730275T3 (es) 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
CN100349612C (zh) * 2005-02-05 2007-11-21 复旦大学 含葡激酶突变体的缓释微球制剂及其制备方法
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
WO2007120368A2 (en) 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
MY148370A (en) 2006-12-18 2013-04-15 Takeda Pharmaceutical Sustained-release composition and method for producing the same
WO2009049350A1 (en) 2007-10-15 2009-04-23 The University Of Queensland Expression system for modulating an immune response
CA2748788C (en) 2009-01-05 2021-02-09 Epitogenesis Inc. The use of a composition comprising mustard oil, catechin, and vitamin a for modulating an immune response
WO2011106705A2 (en) 2010-02-26 2011-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Dna-protein vaccination protocols
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
LT2717914T (lt) * 2011-06-10 2020-03-25 Ramscor, Inc. Sulėtinto atpalaidavimo kompozicijos, skirtos baltymų pateikimui į akį, ir jų paruošimo būdai
JP2014527398A (ja) 2011-06-21 2014-10-16 オンコファクター コーポレイション がんの療法および診断のための組成物および方法
EP2723378A4 (de) 2011-06-24 2015-01-28 Epitogenesis Inc Pharmazeutische zusammensetzungen mit einer kombination aus ausgewählten trägern, vitaminen, tanninen und flavonoiden als antigenspezifischen immunmodulatoren
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
EP2890720B1 (de) 2012-08-30 2019-07-17 The General Hospital Corporation Zusammensetzungen und verfahren zur behandlung von krebs
US10640771B2 (en) 2013-04-17 2020-05-05 Genzyme Corporation Compositions and methods for treating and preventing macular degeneration
EP3848045A1 (de) 2013-05-21 2021-07-14 President and Fellows of Harvard College Manipulierte hämbindende zusammensetzungen und verwendungen davon
WO2015073707A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
KR102234695B1 (ko) 2014-02-06 2021-04-02 젠자임 코포레이션 황반 변성을 치료하고 예방하기 위한 조성물 및 방법
EP3194446B1 (de) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Zusammensetzungen und verfahren zur behandlung von fibrose
EP3270897A4 (de) 2015-03-20 2018-12-05 The Regents Of The University Of Michigan Immunogene zusammensetzungen zur verwendung als impfstoff gegen bordetella
EP3283529B1 (de) 2015-04-17 2023-06-07 The General Hospital Corporation Wirkstoffe, systeme und verfahren zur behandlung von krebs
EP4194001B1 (de) 2015-04-22 2026-03-18 Cedars-Sinai Medical Center Enterisch verabreichte bittere oligopeptide zur behandlung von typ-2-diabetes und fettleibigkeit
ES2959642T3 (es) 2015-05-13 2024-02-27 The Us Secretary Of The Department Of Health And Human Services Metodos y composiciones para inducir una respuesta inmunitaria mediante construcciones con elementos conservados
WO2016196366A1 (en) 2015-05-29 2016-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extension of replicative lifespan in diseases of premature aging using p53 isoforms
US10550379B2 (en) 2015-06-29 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
CN108601951B (zh) 2015-12-09 2022-11-22 金港医疗(澳大利亚)私人有限公司 用于治疗的免疫调节组合物
WO2017222911A1 (en) 2016-06-20 2017-12-28 The Board Of Trustees Of The Leland Stanford Junior University Circular rnas and their use in immunomodulation
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor
CN111344403B (zh) 2017-09-15 2025-05-06 利兰斯坦福初级大学董事会 遗传工程细胞的多元性产生和条形码编制
US20250011787A1 (en) 2021-10-21 2025-01-09 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads Retroelement-generated transcription factor decoys
US20250043269A1 (en) 2021-11-03 2025-02-06 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad Precise Genome Editing Using Retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
US20250215458A1 (en) 2022-03-25 2025-07-03 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Production of reverse transcribed DNA (RT-DNA) using a retron reverse transcriptase from exogenous RNA
US20250215422A1 (en) 2022-03-25 2025-07-03 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads RT-DNA Fidelity and Retron Genome Editing
US20250223586A1 (en) 2022-03-25 2025-07-10 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Methods of assessing engineered retron activity, and uses thereof
JP2025525569A (ja) 2022-07-18 2025-08-05 レナゲード セラピューティクス マネージメント インコーポレイテッド 遺伝子編集成分、システム、及び使用方法
US20250243516A1 (en) 2022-08-24 2025-07-31 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Dual Cut Retron Editors for Genomic Insertions and Deletions
AU2023329392A1 (en) 2022-08-25 2025-02-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024233791A1 (en) 2023-05-11 2024-11-14 Seelos Therapeutics, Inc. Methods of treating neurodegenerative disorders
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2237545A1 (de) * 1972-07-31 1974-02-14 Basf Ag Verfahren zur herstellung von mikrokapseln
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents

Also Published As

Publication number Publication date
JP3512408B2 (ja) 2004-03-29
CA2053913A1 (fr) 1991-08-23
WO1991012882A1 (fr) 1991-09-05
FR2658432B1 (fr) 1994-07-01
DE69103104T2 (de) 1995-01-05
EP0469110B1 (de) 1994-07-27
CA2053913C (fr) 2001-04-03
FR2658432A1 (fr) 1991-08-23
DE69103104D1 (de) 1994-09-01
JPH04505420A (ja) 1992-09-24
EP0469110A1 (de) 1992-02-05

Similar Documents

Publication Publication Date Title
DE69103104D1 (de) Mikrokugeln aus denen wasserlösliche materialien mit vorbestimmter geschwindigkeit freigesetzt werden, und verfahren zur herstellung derselben.
Lee et al. Effect of formulation and processing variables on the characteristics of microspheres for water-soluble drugs prepared by w/o/o double emulsion solvent diffusion method
Wan et al. Drug encapsulation in alginate microspheres by emulsification
DE69505697D1 (de) Biologisch abbaubare mikrosphären mit gesteuerter freigabe und verfahren zu deren herstellung
JP2000511110A (ja) 超臨界流体を使用したマイクロカプセル化方法
CN106421900B (zh) 组织修复支架的3d打印浆料、组织修复支架及其制备方法和应用
DE3382587D1 (de) Injizierbares langwirkendes mikroteilchen-praeparat zur verabreichung entzuendungshemmender mittel.
CA2074320A1 (en) Process for the preparation of microspheres made of a biodegradable polymeric material
DE3777793D1 (de) Verfahren zur herstellung eines kolloidalen, dispersiblen systems von nanokapseln.
GR3025297T3 (en) Method for producing sustained release microsphere preparation
JPH0687758A (ja) Ｌｈｒｈホルモンおよびその類似体を徐々に放出する微小球体の製造方法と、その微小球体と、それを含む製剤
CN114532335B (zh) 一种离子液体型农药微胶囊及其制备方法
JP2008540720A (ja) 再分散可能な固形エマルション
DK0561821T3 (da) Fremgangsmåde til fremstilling af kollagenpartikler og deres anvendelse som bærerstof for aktive stoffer
UCHIDA et al. Preparation and characterization of polylactic acid microspheres containing bovine insulin by aw/o/w emulsion solvent evaporation method
DE60141680D1 (de) Verfahren zur herstellung von mikronisierte gefriergetrocknete partikeln
Kikic et al. Applications of supercritical fluids to pharmaceuticals: controlled drug release systems
JP2811470B2 (ja) マイクロカプセルの表面改質方法
DE59104996D1 (de) Verfahren zur Herstellung von Erdalkalialkoholaten mit sphärischem Partikelhabitus.
US5990183A (en) Porous particles, porous hollow particles and method of preparing such particles
JP2011201780A (ja) 水溶性殺虫粒剤
JP3634110B2 (ja) 徐放性粒子の製造方法
Iwata Particle size and loading efficiency of poly (D, L-lactic-coglycolic acid) multiphase microspheres containing water soluble substances prepared by the hydrous and anhydrous solvent evaporation methods
Sreenivasan Application of molecularly imprinted polymer as a drug retaining matrix
Zhai et al. Synthesis of polydopamine capsules via SPG membrane emulsion templating: Tuning of capsule size

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties